Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients

…, F Buron, G Gautier-Vargas, M Delafosse… - Science Translational …, 2022 - science.org
Transplant recipients, who receive therapeutic immunosuppression to prevent graft rejection,
are characterized by high coronavirus disease 2019 (COVID-19)–related mortality and …

Comparison of infected and vaccinated transplant recipients highlights the role of Tfh and neutralizing IgG in COVID-19 protection

…, F Heibel, F Buron, G Gautier-Vargas, M Delafosse… - MedRxiv, 2021 - medrxiv.org
Transplant recipients, which receive therapeutic immunosuppression to prevent graft rejection,
are characterized by high COVID-19-related mortality and defective response to vaccines…

Models of glomerular filtration barrier: New developments

M Dembele, M Delafosse, N Yousfi, H Debiec… - … Sciences: M/S, 2021 - europepmc.org
In this article, we present the latest innovations to generate in vitro models of the glomerular
filtration barrier. There is currently a growing interest for such model systems that allow to …

Severe tubulointerstitial nephritis: tracking tuberculosis even in the absence of renal granuloma

M Delafosse, C Teuma, P Miailhes… - Clinical Kidney …, 2018 - academic.oup.com
Extra-pulmonary tuberculosis is frequently located in the kidneys and, in such cases, could
be associated with a granulomatous interstitial nephritis. Granulomas are not always detected…

Personalized phospholipase A2 receptor antibody–driven rituximab treatment strategy in membranous nephropathy

M Delafosse, E Ponlot, E Esteve… - Kidney …, 2021 - kidney-international.org
2. Van de Logt A, Dahan K, Rousseau A, et al. Immunological remission in PLA2R-antibody-associated
membranous nephropathy: cyclophosphamide versus rituximab. Kidney Int. 2018…

[HTML][HTML] Modélisation de la barrière de filtration glomérulaire-Nouvelles avancées

M Dembele, M Delafosse, N Yousfi… - médecine …, 2021 - medecinesciences.org
Nous présentons, dans cette revue, les dernières avancées concernant la modélisation in
vitro de la barrière de filtration glomérulaire. Ces systèmes, permettant de réduire l’utilisation …

Steroids: A Therapeutic Option for COVID-19 Pneumonia Patients With ESRD?

M Delafosse, C Saint-Jaques, C Petit-Hoang… - Kidney International …, 2020 - Elsevier
Alberici et al proposed in a recent review some therapeutic approaches for patients with end-stage
renal disease (ESRD) and infected with COVID-19 (1). They notably suggest the use …

Lung cancer trends and tumor characteristic changes over 20 years (2000–2020): Results of three French consecutive nationwide prospective cohorts' studies

…, C Decroisette, S Dehette, C Delafosse… - The Lancet Regional …, 2022 - thelancet.com
Background Long-term changes in lung cancer (LC) patients are difficult to evaluate. We report
results from the French KBP-2020 real-life cohort. Methods KBP-2020 was a prospective …

Serum Albumin Still of Interest to Predict Outcomes in Membranous Nephropathy in the Era of Phospholipase A2 Receptor

M Delafosse, E Ponlot, N Hanset, E Estève… - Kidney International …, 2020 - kireports.org
To the Editor: In a recent retrospective study, Lee et al. 1 demonstrated the interest of serum
albumin (sAlb) as a prognostic marker of outcome in primary membranous nephropathy. The …

[CITATION][C] Relecteurs 2022 pour Néphrologie & Thérapeutique

…, L Mercadal, M Bauwens, M Delafosse… - Néphrologie & …, 2022 - jle.com
JLE - Néphrologie & Thérapeutique - Relecteurs 2022 pour Nephrologie & Therapeutique
JLE Home Bookstore Search for books Collections New books and E-books Publishers …